- Omeros Corporation OMER has revealed that the FDA needs additional time to review narsoplimab marketing application for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
- The new target action date is October 17, compared to the earlier date of July 17.
- Omeros recently submitted a response to an FDA information request. FDA has classified the response as a major amendment, which requires additional time to review.
- Price Action: OMER shares are down 12% at $14.92 on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
